Janney Montgomery Scott LLC Editas Medicine, Inc. Transaction History

Janney Montgomery Scott LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 28, 2023	BUY	$7.03 - $11.53 $80,345 - $131,776	11,429 New	11,429 $83,000
Q3 2022 Oct 25, 2022	BUY	$12.16 - $19.42 $2,894 - $4,621	238 Added 1.13%	21,373 $262,000
Q2 2022 Aug 03, 2022	SELL	$9.99 - $21.35 $87,832 - $187,709	-8,792 Reduced 29.38%	21,135 $263,000
Q1 2022 May 04, 2022	BUY	$14.08 - $27.63 $125,213 - $245,713	8,893 Added 42.28%	29,927 $569,000
Q4 2021 Jan 27, 2022	SELL	$26.55 - $40.57 $187,549 - $286,586	-7,064 Reduced 25.14%	21,034 $558,000
Q3 2021 Oct 29, 2021	BUY	$39.27 - $72.94 $705,367 - $1.31 Million	17,962 Added 177.21%	28,098 $1.15 Million
Q2 2021 Jul 26, 2021	BUY	$31.29 - $56.64 $122,343 - $221,462	3,910 Added 62.8%	10,136 $574,000
Q1 2021 Apr 27, 2021	BUY	$39.71 - $90.58 $247,234 - $563,951	6,226 New	6,226 $261,000

228

54.2M

412K

355K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Janney Montgomery Scott LLC, based on Form 13F filings with the SEC.

Stay updated on Janney Montgomery Scott LLC with notifications on news.